Hongyuan Pharmaceutical released its 2026 interim report, with total operating revenue of 1.342 billion yuan and net profit attributable to the parent company of 156 million yuan. Net cash inflow from operating activities was 39.5168 million yuan, ranking 90th among peer companies that have disclosed results. The company's asset-liability ratio was 28.18 percent, up 1.51 percentage points from the previous quarter and up 1.44 percentage points from the same period last year. Gross margin was 23.07 percent, down 8.94 percentage points from the previous quarter. Return on equity was 3.39 percent, and diluted earnings per share was 0.39 yuan. The number of shareholders was 30,700, and the top ten shareholders held 59.58 percent of total share capital.
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. AInterim report shows net profit of 156 million yuan, but gross margin declined significantly, presenting mixed financial results.